Extended Ebglyss Maintenance Dosing Approved for Atopic Dermatitis Dermatology Advisor 16:41 Fri, 12 Jun
FDA approves Lilly's Ebglyss® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis PR Newswire (Press Release) 23:20 Tue, 09 Jun